Zai Lab's revenue growth has decelerated sharply from 65.7% in 2024Q4 to -3.3% in 2026Q2, while gross margins compressed from 64.9% to 54.7% over the same period, indicating eroding pricing power and a loss of commercial momentum.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.41+30.7% vs -$0.59 | $108M+0.3% vs $108M |
Q3 2026 Aug 6, 2026 | -$0.46+32.3% vs -$0.68 | $106M+2.4% vs $104M |
Q2 2026 May 7, 2026 | -$0.46+12.6% vs -$0.53 | $100M-8.1% vs $108M |
Q1 2026 Feb 26, 2026 | -$0.46-4.5% vs -$0.44 | $128M+4.4% vs $122M |
Zai Lab NASDAQ: ZLAB reported $108.2 million in third-quarter revenue and said it expects to return to year-over-year product revenue growth in 2027, while advancing its lead cancer drug candidate toward potential U.S. regulatory submissions next year.
Zai Lab Limited (ZLAB) Q3 2026 Earnings Call Transcript
While the top- and bottom-line numbers for Zai Lab Limited (ZLAB) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, today announced that updated data from a Phase 1b/2 trial of zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), will be shared tomorrow at the North American Neuroendocrine Tumor Society (NANETS) 2026 Multidisciplinary NET Medical Symposium in Las Vegas. The data indicate that zoci demonstrated clinically meaningf.
Benchmark ZLAB against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Zai Lab Limited (ZLAB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $25.48 | $2.88B | -14.43 | 15.33% | -44.91% | -31.15% | — | |
| $23.40 | $4.33B | -49.50 | 64.04% | -7.21% | -8.7% | — | |
| $29.63 | $2.18B | -14.42 | 38.87% | -404% | -72.07% | — | |
| $0.19 | $134.43M | -0.45 | 96.69% | -67.79% | -80.25% | — | |
| $18.28 | $2.3B | -5.23 | -4.26% | -445% | -90.04% | — | |
| $30.53 | $6.3B | -11.66 | — | -7585.86% | -69.59% | — |
Zai Lab Limited (ZLAB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Zai Lab Limited (ZLAB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jun 17, 2026·SEC
May 21, 2026·SEC
Get notified when ZLAB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Zai Lab Limited (ZLAB) stock FAQ — growth, dividends, profitability & financials explained
Zai Lab Limited (ZLAB) reported $441.7M in revenue over the trailing twelve months. Revenue was $460.2M in fiscal year 2025.
Zai Lab Limited (ZLAB) grew revenue by 0.0% over the trailing twelve months, compared with the twelve months before.
No. Zai Lab Limited (ZLAB) reported a net loss of $198.4M over the trailing twelve months.
Zai Lab Limited (ZLAB) had a return on equity (ROE) of -31.1% over the trailing twelve months. A negative ROE means the company lost money over the period.
Zai Lab Limited (ZLAB) had negative free cash flow of $164.0M over the trailing twelve months.
